Ser745

Site Information
sSASTALsQDIPEIA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 472359
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 3 ) , 'brain, embryonic' ( 11 , 13 ) , brain ( 5 , 12 , 14 ) , heart ( 5 ) , liver ( 5 ) , lung ( 5 ) , MC3T3-E1 (preosteoblast) ( 2 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 4 ) , MEF (fibroblast) ( 4 ) , spleen ( 5 ) , testis ( 5 )

Upstream Regulation
Treatments:	insulin ( 3 ) , MK-2206 ( 3 )

References
1	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
2	Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50 26160508 Curated Info
3	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
4	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
5	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
6	Rikova K (2008) CST Curation Set: 5291; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
7	Rikova K (2008) CST Curation Set: 5292; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
8	Rikova K (2008) CST Curation Set: 5293; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
9	Rikova K (2008) CST Curation Set: 5295; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
10	Rikova K (2008) CST Curation Set: 5296; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-4/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
11	Guo A (2007) CST Curation Set: 2672; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
12	Guo A (2007) CST Curation Set: 2675; Year: 2007; Biosample/Treatment: tissue, brain/LY; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
13	Guo A (2007) CST Curation Set: 2677; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
14	Guo A (2007) CST Curation Set: 2682; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info